MedTrace Logo

Open-Label Safety Extension Study of Avonex

NCT00915460 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2009-06-08

No results posted yet for this study

Summary

To collect data on serious adverse events which occur during extended treatment with Avonex in subjects at high risk for developing multiple sclerosis (MS) and in subjects with secondary progressive MS.

Conditions

Interventions

DRUG

Interferon beta-1a (Avonex)

dosage and frequency as per Biogen Idec protocol

Sponsors & Collaborators

Principal Investigators

  • Biogen-Idec Investigator · Biogen

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2003-06-30
Completion
2003-07-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00915460 on ClinicalTrials.gov